Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $48.6M | $351M | — | — | — | — |
| Revenue growth | — | — | — | 622.5% | — | — | — | — |
| Operating income | -$9.48M | -$14.6M | -$11.0M | $138M | -$131M | -$164M | -$193M | -$181M |
| Operating margin | — | — | -22.7% | 39.4% | — | — | — | — |
| Net income | -$9.06M | -$14.0M | -$10.9M | $121M | -$116M | -$136M | -$168M | -$158M |
| Net margin | — | — | -22.5% | 34.5% | — | — | — | — |
| EPS (diluted) | -$0.90 | -$1.39 | -$0.51 | $1.37 | -$1.39 | -$1.63 | -$2.00 | -$1.94 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.91M | -$12.8M | $297M | -$87.0M | -$121M | -$85.4M | -$135M | -$132M |
| Capital expenditures | $12.0K | $2.00K | $26.0K | $4.00K | $1.94M | — | — | — |
| Free cash flow | -$7.92M | -$12.8M | $297M | -$87.0M | -$123M | — | — | — |
| Share buybacks | — | — | — | — | — | — | $0.00 | $25.5M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $34.5M | $21.7M | $850M | $764M | $188M | $144M | $64.7M | $95.7M |
| Total assets | — | $22.1M | $864M | $773M | $667M | $595M | $465M | $315M |
| Total liabilities | — | $2.53M | $316M | $62.8M | $26.1M | $39.8M | $25.8M | $39.8M |
| Shareholders' equity | -$36.2M | -$49.6M | $548M | $710M | $641M | $555M | $439M | $275M |
| Retained earnings | — | -$54.2M | -$65.2M | $56.0M | -$59.9M | -$196M | -$364M | -$523M |
| Shares (wtd avg diluted) | — | 10.1M | 21.6M | 88.2M | 83.2M | 83.4M | 84.3M | 81.5M |
Every figure is extracted from Atea Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.